Ponatinib (for Ph+ ALL)
Treatment for Acute Lymphoid Leukemia
Typical Dosage: 15 mg to 45 mg orally once daily
Effectiveness
83%
Safety Score
45%
Clinical Trials
20
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanideโ ๏ธ
Meth๐
Cigarettes๐ฌ
Chemoโข๏ธ
Alcohol๐บ
Morphine๐
Antibiotics๐
Tylenol๐
Exercise๐
Water๐ง
45
DangerousModerateSafe
Treatment Details
Dosage Range
15 mg to 45 mg orally once daily
Time to Effect
8-12 weeks (for molecular response)
Treatment Duration
Long-term (years, often combined with chemotherapy)
Evidence Quality
MODERATEConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$20,000
Side Effect Mgmt:$30,000
Total Annual:$250,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
1.5
Outcome-Based Costs
Cost per Responder
$357,143
Cost per Remission
$454,545
Comparison vs Dasatinib
Cost Difference
+$65,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Ponatinib (for Ph+ ALL) Outcomes
for Acute Lymphoid Leukemia
Efficacy Outcomes
Overall Effectiveness
+83%
Response Rate
+70%
Remission Rate
+55%
Common Side Effects
Arterial occlusive events
+20%
Hypertension
+60%
Myelosuppression
+50%
Pancreatitis
+10%
Hepatotoxicity
+20%
Fluid retention
+40%
Active Clinical Trials
10 active trials recruiting for Ponatinib (for Ph+ ALL) in Acute Lymphoid Leukemia
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
NCT04475731ACTIVE NOT RECRUITINGPHASE2
67 participants
INTERVENTIONAL
Ancona, Italy +21 more
Started: May 4, 2021
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
NCT04233346ACTIVE NOT RECRUITINGPHASE2
93 participants
INTERVENTIONAL
Hefei, China +13 more
Started: Jul 9, 2020
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094RECRUITINGPHASE2
220 participants
INTERVENTIONAL
Aachen, Germany +84 more
Started: Jul 14, 2023
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
NCT04747912RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Chicago, United States
Started: Mar 2, 2021
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848ACTIVE NOT RECRUITINGPHASE3
236 participants
INTERVENTIONAL
Ascoli Piceno, Italy +14 more
Started: Sep 8, 2021
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
NCT07614022NOT YET RECRUITINGPHASE1
26 participants
INTERVENTIONAL
Charlotte, United States +1 more
Started: Oct 1, 2026
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326ACTIVE NOT RECRUITINGPHASE3
245 participants
INTERVENTIONAL
Birmingham, United States +91 more
Started: Oct 4, 2018
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
NCT03739814RECRUITINGPHASE2
84 participants
INTERVENTIONAL
Birmingham, United States +279 more
Started: May 8, 2019
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
NCT06175702NOT YET RECRUITING
150 participants
OBSERVATIONAL
Started: Dec 25, 2023
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
NCT07224100RECRUITINGPHASE2
33 participants
INTERVENTIONAL
Seattle, United States
Started: Mar 30, 2026
Completed Clinical Trials
4 completed trials for Ponatinib (for Ph+ ALL) in Acute Lymphoid Leukemia
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
NCT01207440COMPLETEDPHASE2
449 participants
INTERVENTIONAL
St Leonards, Australia +41 more
Started: Sep 30, 2010
Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
NCT01641107COMPLETEDPHASE2
44 participants
INTERVENTIONAL
Alessandria, Italy +41 more
Started: Dec 4, 2014
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
NCT01667133COMPLETEDPHASE1, PHASE2
35 participants
INTERVENTIONAL
Nagoya, Japan +10 more
Started: Aug 31, 2012
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I
NCT02981784COMPLETED
184 participants
OBSERVATIONAL
Pierre-Bรฉnite, France
Started: Jan 1, 2000
Showing 20 of 23 total trials